Welcome to our dedicated page for Synergy Chc SEC filings (Ticker: SNYR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Synergy CHC Corp. (NASDAQ: SNYR) SEC filings page brings together the company’s official disclosures as a smaller reporting company in the consumer health and wellness sector. Synergy develops and markets branded products such as FOCUSfactor® brain-health supplements and functional beverages and Flat Tummy® women’s wellness offerings, and its regulatory filings provide detailed insight into how this business is structured and financed.
Through annual reports on Form 10‑K and quarterly reports on Form 10‑Q, Synergy reports product sales, license revenue, gross profit, operating expenses, operating income, net income, and non‑GAAP measures like EBITDA and Adjusted EBITDA. These filings also describe working capital, inventory levels, debt obligations, and stockholders’ equity or deficit, giving investors a view of how the company funds expansion of its FOCUSfactor® and Flat Tummy® brands.
Current reports on Form 8‑K document material events such as quarterly earnings releases, public offerings of common stock, changes to equity incentive plans, authorization of preferred stock, and board or executive changes. For example, Synergy has used Form 8‑K to report an underwritten public offering of common stock, amendments to its 2024 Equity Incentive Plan, authorization of preferred stock, and governance updates including director appointments and role transitions.
Registration statements such as the Form S‑1 provide additional background on the company’s business, risk factors, use of proceeds, capital structure, and status as a smaller reporting company. Investors interested in ownership changes and executive incentives can review equity plan amendments and related disclosures within these filings. On this page, AI-powered tools can help summarize lengthy documents, highlight key financial and governance changes, and make complex sections of 10‑K, 10‑Q, 8‑K, and S‑1 filings easier to understand.
Use this filings hub to track Synergy CHC Corp.’s official financial reporting, capital raises, governance actions, and other regulatory disclosures that shape the outlook for SNYR stock.
Synergy CHC Corp. received a non-compliance notice from Nasdaq after its common stock closed below $1.00 per share for 30 consecutive business days, violating the Nasdaq Capital Market minimum bid price rule.
The company has 180 calendar days, until November 11, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for 10 straight business days. If it meets other Nasdaq listing standards, it may qualify for an additional 180-day grace period. Failing to regain compliance could lead to delisting, and management is monitoring the share price and may consider options such as a reverse stock split.
Synergy CHC Corp. is registering 101,710,000 shares of common stock for resale by Hudson Global Ventures, LLC under a Form S-1. The registered shares consist of 100,000,000 equity line (ELOC) shares, 1,540,000 warrant shares and 170,000 existing shares issued for prior consulting services.
The company will not receive proceeds from the selling stockholder’s resales, but may raise up to $36,000,000 over about 24 months by selling ELOC shares directly to Hudson under an Equity Purchase Agreement. As of May 14, 2026, 14,899,883 shares of common stock were outstanding, and the last reported Nasdaq price was $0.30 per share.
The filing also highlights Synergy’s nutraceutical brands FOCUSfactor and Flat Tummy, with 2025 revenue of $30.4 million, net loss of $(12.3) million and EBITDA of $(6.2) million, compared with 2024 revenue of $34.8 million, net income of $2.1 million and EBITDA of $6.5 million. Management attributes 2025 pressures partly to bad-debt and inventory write-offs.
Synergy CHC Corp. reported weaker results for the quarter ended March 31, 2026. Revenue fell to $5.49 million from $8.17 million a year earlier as prior-year license revenue of $1.5 million did not repeat and online sales were hurt by out-of-stock issues in the Flat Tummy brand.
Despite over $650,000 in functional beverage revenue and an estimated beverage annual run rate above $4 million, profitability deteriorated. The company posted an operating loss of $0.57 million, a net loss of $2.57 million, and a basic and diluted loss per share of $0.23, versus net income of $0.88 million and earnings per share of $0.10 in the prior-year quarter.
Cash and cash equivalents declined to about $0.30 million as of March 31, 2026 from $2.6 million at December 31, 2025, and the company moved to a working capital deficit of $0.50 million. Total liabilities were $31.87 million against a stockholders’ deficit of $25.41 million. After quarter-end, Synergy raised approximately $2.7 million in gross proceeds through an at-the-market equity program to bolster liquidity.
Synergy CHC Corp. reported a Q1 2026 net loss of $2,568,899, compared with net income of $876,264 a year earlier, as revenue declined and interest costs rose. Revenue fell to $5,492,705 from $8,170,534, mainly due to lower nutraceutical and online sales and the absence of prior-year license revenue.
Gross margin remained high at 72% but dollar gross profit dropped to $3,970,795. Operating expenses increased to $4,537,915, driven by higher salaries, professional fees and stock-based compensation. Interest expense nearly doubled to $2,012,121, reflecting the new $17,500,000 term loan and receivables advances.
At March 31, 2026, cash was $292,115 with total assets of $6,461,591 versus total liabilities of $31,866,841, leaving a stockholders’ deficit of $25,405,250. Management evaluated going concern and concluded it expects to meet obligations over the next year, but leverage and liquidity remain tight.
Synergy CHC Corp. entered into an equity purchase agreement with Hudson Global Ventures giving the company the right, but not the obligation, to sell up to $36,000,000 of common stock over 24 months. Each draw must be at least $25,000 and no more than the lesser of $2,500,000 or 200% of recent average trading volume, with shares priced at 95% of specified market prices.
As consideration, Hudson received a warrant to buy 1,540,000 common shares at $0.01 per share, exercisable for five years, subject to a 4.99% beneficial ownership cap and an exchange cap tied to Nasdaq rules. Synergy agreed to register resale of shares under a registration rights agreement, avoid other equity lines and limit variable-rate financings, with certain rights of first refusal in favor of Hudson.
Synergy CHC Corp. is asking stockholders to approve several major items at its 2026 virtual annual meeting on June 29, 2026. Stockholders will vote on electing five directors and ratifying RBSM LLP as auditor for 2026.
They are also asked to approve an amendment to the 2024 Equity Incentive Plan to increase the share reserve to 150,000,000 common shares and allow repricing of outstanding awards, approve the full issuance of shares upon exercise of a Lender Warrant under Nasdaq Rules 5635(b) and 5635(d), and authorize one or more reverse stock splits at ratios up to 1‑for‑200. As of April 24, 2026, Synergy CHC had 14,899,883 common shares outstanding.
Synergy CHC Corp. director Kaushal Nitin received a stock-based compensation award of 306,433 restricted stock units on common stock. The award was reported as a grant or other acquisition with no cash price per share. According to the terms, each RSU represents a contingent right to one common share and the RSUs vested in full on the grant date. Following this grant, Nitin directly holds 306,433 common shares associated with this award.
Synergy CHC Corp. director Teresa Brigid Thompson received an equity award of 25,824 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Synergy CHC common stock.
The RSUs were granted and fully vested on the grant date, with no cash exercise price. Following this award, Thompson holds 25,824 shares of common stock directly, reflecting a routine compensation-related grant under Synergy CHC’s 2024 Equity Incentive Plan.